Open AccessKeeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery
Author(s) -
SteinMerlob Ashley F.,
Hsu Jeffrey J.,
Colton Bradley,
Berg Christopher J.,
Ferreira Allison,
Price Megan M.,
Wainberg Zev,
Baas Arnold S.,
Deng Mario C.,
Parikh Rushi V.,
Yang Eric H.
Publication year - 2021
Publication title -
esc heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.787
H-Index - 25
ISSN - 2055-5822
DOI - 10.1002/ehf2.13545
Subject(s) - cardiogenic shock , medicine , myocarditis , fulminant , circulatory system , nivolumab , heart failure , cardiomyopathy , immunosuppression , shock (circulatory) , cardiology , immunotherapy , complication , cancer , myocardial infarction
Immune checkpoint inhibitor (ICI)‐associated myocarditis is a rare, potentially life‐threatening complication of immunotherapy. We report a case of a 60‐year‐old female with a history of colorectal cancer treated with nivolumab immunotherapy who presented with new cardiomyopathy complicated by cardiogenic shock and ventricular arrhythmias. Treatment of ICI‐associated myocarditis requires aggressive immunosuppression and supportive therapy. In this case, the patient required advanced mechanical circulatory support as a bridge to recovery. This case highlights the complexity of diagnosis, haemodynamic management, and treatment of fulminant ICI myocarditis.